BUZZ-Scholar Rock hits 3-year high on rival Biohaven's drug setback** Drugmaker Scholar Rock Holding's shares SRRK.O rise 32.2% to a roughly 3-year high of $39.45
** SRRK's rival Biohaven BHVN.N said on Monday its experimental treatment for a rare neuromuscular disorder failed to meet the main goal of improving patients' motor function in a late-stage trial
** Truist analysts raise their peak sales estimate on apitegromab, SRRK's drug for the same disorder, called spinal muscular atrophy, to $1.5 bln from $1.2 bln after Biohaven's announcement
** SRRK shares surged over 360% on Oct. 7 after apitegromab met the main goal of a late-stage trial; shares have doubled YTD
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments